Antoine Brouquet1, Léon Maggiori2, Philippe Zerbib3, Jérémie H Lefevre4, Quentin Denost5, Adeline Germain6, Eddy Cotte7, Laura Beyer-Berjot8, Nicolas Munoz-Bongrand9, Véronique Desfourneaux10, Amine Rahili11, Jean-Pierre Duffas12, Karine Pautrat13, Christine Denet14, Valérie Bridoux15, Guillaume Meurette16, Jean-Luc Faucheron17, Jérome Loriau18, Françoise Guillon19, Eric Vicaut20, Stéphane Benoist1, Yves Panis2. 1. Digestive Surgery Department, Bicetre Hospital, APHP, Paris-Sud University, Le Kremlin-Bicetre, France. 2. Department of Colorectal Surgery, Beaujon Hospital, APHP, Paris VII University, Clichy, France. 3. Digestive Surgery Department, Univeristy Hospital of Lille, Lille, France. 4. Digestive Surgery Department, Saint-Antoine Hospital Saint-Antoine, APHP, Paris VI University, Paris, France. 5. Digestive Surgery Department, Saint-Andre University Hospital, Bordeaux, France. 6. Digestive Surgery Department, University Hospital of Nancy, Nancy, France. 7. Digestive Surgery Department, Lyon-Sud University Hospital, Pierre-Benite, France. 8. Digestive Surgery Department, Marseille-Nord University Hospital, Marseille, France. 9. Digestive Surgery Department, Saint-Louis Hospital, Paris VII University, Paris, France. 10. Digestive Surgery Department, University Hospital of Rennes, Rennes, France. 11. Digestive Surgery Department, University Hospital of Nice, Nice, France. 12. Digestive Surgery Department, Rangueil University Hospital, Toulouse, France. 13. Digestive Surgery Department, Lariboisiere Hospital, Paris VII University, Paris, France. 14. Digestive Surgery Department, Montsouris Institute, Paris, France. 15. Digestive Surgery Department, University Hospital of Rouen, Rouen, France. 16. Digestive Surgery Department, University Hospital of Nantes, Nantes, France. 17. Digestive Surgery Department, Digestive Surgery Department, University Hospital of Grenoble, La Tronche, France. 18. Digestive Surgery Department, Saint-Joseph Hospital, Paris, France. 19. Digestive Surgery Department, University Hospital of Montpellier, Montpellier, France. 20. Department of Clinical Research, Fernand Widal Hospital , APHP, Paris VII, Paris, France.
Abstract
OBJECTIVE: To determine the risk factors of morbidity after surgery for ileocolonic Crohn disease (CD). SUMMARY BACKGROUND DATA: The risk factors of morbidity after surgery for CD, particularly the role of anti-TNF therapy, remain controversial and have not been evaluated in a large prospective cohort study. METHODS: From 2013 to 2015, data on 592 consecutive patients who underwent surgery for CD in 19 French specialty centers were collected prospectively. Possible relationships between anti-TNF and postoperative overall morbidity were tested by univariate and multivariate analyses. Because treatment by anti-TNF is possibly dependent on the characteristics of the patients and disease, a propensity score was calculated and introduced in the analyses using adjustment of the inverse probability of treatment-weighted method. RESULTS: Postoperative mortality, overall and intra-abdominal septic morbidity rates in the entire cohort were 0%, 29.7%, and 8.4%, respectively; 143 (24.1%) patients had received anti-TNF <3 months prior to surgery. In the multivariate analysis, anti-TNF <3 months prior to surgery was identified as an independent risk factor of the overall postoperative morbidity (odds-ratio [OR] =1.99; confidence interval [CI] 95% = 1.17-3.39, P = 0.011), with preoperative hemoglobin <10 g/dL (OR = 4.77; CI 95% = 1.32-17.35, P = 0.017), operative time >180 min (OR = 2.71; CI 95% = 1.54-4.78, P < 0.001) and recurrent CD (OR = 1.99; CI 95% = 1.13-3.36, P = 0.017). After calculating the propensity score and adjustment according to the inverse probability of treatment-weighted method, anti-TNF <3 months prior to surgery remained associated with a higher risk of overall (OR = 2.98; CI 95% = 2.04-4.35, P <0.0001) and intra-abdominal septic postoperative morbidities (OR = 2.22; CI 95% = 1.22-4.04, P = 0.009). CONCLUSIONS: Preoperative anti-TNF therapy is associated with a higher risk of morbidity after surgery for ileocolonic CD. This information should be considered in the surgical management of these patients, particularly with regard to the preoperative preparation and indication of temporary defunctioning stoma.
OBJECTIVE: To determine the risk factors of morbidity after surgery for ileocolonic Crohn disease (CD). SUMMARY BACKGROUND DATA: The risk factors of morbidity after surgery for CD, particularly the role of anti-TNF therapy, remain controversial and have not been evaluated in a large prospective cohort study. METHODS: From 2013 to 2015, data on 592 consecutive patients who underwent surgery for CD in 19 French specialty centers were collected prospectively. Possible relationships between anti-TNF and postoperative overall morbidity were tested by univariate and multivariate analyses. Because treatment by anti-TNF is possibly dependent on the characteristics of the patients and disease, a propensity score was calculated and introduced in the analyses using adjustment of the inverse probability of treatment-weighted method. RESULTS: Postoperative mortality, overall and intra-abdominal septic morbidity rates in the entire cohort were 0%, 29.7%, and 8.4%, respectively; 143 (24.1%) patients had received anti-TNF <3 months prior to surgery. In the multivariate analysis, anti-TNF <3 months prior to surgery was identified as an independent risk factor of the overall postoperative morbidity (odds-ratio [OR] =1.99; confidence interval [CI] 95% = 1.17-3.39, P = 0.011), with preoperative hemoglobin <10 g/dL (OR = 4.77; CI 95% = 1.32-17.35, P = 0.017), operative time >180 min (OR = 2.71; CI 95% = 1.54-4.78, P < 0.001) and recurrent CD (OR = 1.99; CI 95% = 1.13-3.36, P = 0.017). After calculating the propensity score and adjustment according to the inverse probability of treatment-weighted method, anti-TNF <3 months prior to surgery remained associated with a higher risk of overall (OR = 2.98; CI 95% = 2.04-4.35, P <0.0001) and intra-abdominal septic postoperative morbidities (OR = 2.22; CI 95% = 1.22-4.04, P = 0.009). CONCLUSIONS: Preoperative anti-TNF therapy is associated with a higher risk of morbidity after surgery for ileocolonic CD. This information should be considered in the surgical management of these patients, particularly with regard to the preoperative preparation and indication of temporary defunctioning stoma.
Authors: Igors Iesalnieks; A Spinelli; M Frasson; F Di Candido; B Scheef; N Horesh; M Iborra; H J Schlitt; A El-Hussuna Journal: Tech Coloproctol Date: 2018-12-12 Impact factor: 3.781
Authors: Peter Wilhelm; Andreas Kirschniak; Jonas Johannink; Sascha Kaufmann; Thomas Klag; Jan Wehkamp; Claudius Falch Journal: Int J Colorectal Dis Date: 2018-11-29 Impact factor: 2.571
Authors: G Luglio; L Pellegrini; A Rispo; F P Tropeano; N Imperatore; G Pagano; A Amendola; A Testa; G D De Palma; F Castiglione Journal: Int J Colorectal Dis Date: 2022-01-11 Impact factor: 2.571
Authors: Yong Sik Yoon; Luca Stocchi; Stefan Holubar; Alexandra Aiello; Sherief Shawki; Emre Gorgun; Scott R Steele; Conor P Delaney; Tracy Hull Journal: Surg Endosc Date: 2020-05-28 Impact factor: 4.584
Authors: Afif N Kulaylat; Audrey S Kulaylat; Eric W Schaefer; Katelin Mirkin; Andrew Tinsley; Emmanuelle Williams; Walter A Koltun; Christopher S Hollenbeak; Evangelos Messaris Journal: J Gastrointest Surg Date: 2020-01-21 Impact factor: 3.452
Authors: Jurij Hanzel; Ahmed Almradi; Alexandra C Istl; Mei Lucy Yang; Katherine A Fleshner; Claire E Parker; Leonardo Guizzetti; Christopher Ma; Siddharth Singh; Vipul Jairath Journal: Dig Dis Sci Date: 2021-02-26 Impact factor: 3.199
Authors: Ravi S Shah; Salam Bachour; Xue Jia; Stefan D Holubar; Tracy L Hull; Jean-Paul Achkar; Jessica Philpott; Taha Qazi; Florian Rieder; Benjamin L Cohen; Miguel D Regueiro; Amy L Lightner; Benjamin H Click Journal: J Crohns Colitis Date: 2021-07-05 Impact factor: 9.071